Judy Lieberman

Publications

1. Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity. Cell. 2024 Oct 31; 187(22):6165-6181.e22. View Abstract
2. Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation. Nat Immunol. 2024 Oct; 25(10):1858-1870. View Abstract
3. Inflammasome-independent pyroptosis. Curr Opin Immunol. 2024 Jun; 88:102432. View Abstract
4. Poking holes in the blood-brain barrier. Immunity. 2024 06 11; 57(6):1192-1194. View Abstract
5. The palmitoylation of gasdermin D directs its membrane translocation and pore formation during pyroptosis. Sci Immunol. 2024 Apr 12; 9(94):eadn1452. View Abstract
6. ROS-dependent S-palmitoylation activates cleaved and intact gasdermin D. Nature. 2024 Jun; 630(8016):437-446. View Abstract
7. MALAT1 protects dormant tumor cells from immune elimination. Nat Cancer. 2024 Feb; 5(2):218-220. View Abstract
8. Pregnancy trained decidual NK cells protect pregnancies from harmful Fusobacterium nucleatum infection. PLoS Pathog. 2024 Jan; 20(1):e1011923. View Abstract
9. Gasdermin D permeabilization of mitochondrial inner and outer membranes accelerates and enhances pyroptosis. Immunity. 2023 11 14; 56(11):2523-2541.e8. View Abstract
10. Correction for Song et al., "Sustained Small Interfering RNA-Mediated Human Immunodeficiency Virus Type 1 Inhibition in Primary Macrophages". J Virol. 2023 Oct 31; 97(10):e0093623. View Abstract
11. Accumulation of Neutrophil Phagocytic Antibody Features Tracks With Naturally Acquired Immunity Against Malaria in Children. J Infect Dis. 2023 09 15; 228(6):759-768. View Abstract
12. Disulfiram blocks inflammatory TLR4 signaling by targeting MD-2. Proc Natl Acad Sci U S A. 2023 08; 120(31):e2306399120. View Abstract
13. NOP16 is a histone mimetic that regulates Histone H3K27 methylation and gene repression. bioRxiv. 2023 Jun 13. View Abstract
14. Publisher Correction: The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature. 2023 Jun; 618(7964):E17. View Abstract
15. Alternative splicing of GSDMB modulates killer lymphocyte-triggered pyroptosis. Sci Immunol. 2023 04 28; 8(82):eadg3196. View Abstract
16. The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells. Nature. 2023 04; 616(7956):348-356. View Abstract
17. Gasdermin-E mediates mitochondrial damage in axons and neurodegeneration. Neuron. 2023 04 19; 111(8):1222-1240.e9. View Abstract
18. ROS-dependent palmitoylation is an obligate licensing modification for GSDMD pore formation. bioRxiv. 2023 03 07. View Abstract
19. Palmitoylation of gasdermin D directs its membrane translocation and pore formation in pyroptosis. bioRxiv. 2023 Feb 21. View Abstract
20. The SET oncoprotein promotes estrogen-induced transcription by facilitating establishment of active chromatin. Proc Natl Acad Sci U S A. 2023 02 21; 120(8):e2206878120. View Abstract
21. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nat Cancer. 2022 10; 3(10):1228-1246. View Abstract
22. Author Correction: Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis. Nature. 2022 Aug; 608(7923):E28. View Abstract
23. mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis. Front Immunol. 2022; 13:899975. View Abstract
24. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature. 2022 06; 606(7914):585-593. View Abstract
25. Fc?R-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022 06; 606(7914):576-584. View Abstract
26. Inflammasome activation in infected macrophages drives COVID-19 pathology. bioRxiv. 2022 Apr 01. View Abstract
27. Targeting stem-loop 1 of the SARS-CoV-2 5' UTR to suppress viral translation and Nsp1 evasion. Proc Natl Acad Sci U S A. 2022 03 01; 119(9). View Abstract
28. Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis. Nature. 2022 02; 602(7897):496-502. View Abstract
29. SPARCLE, a p53-induced lncRNA, controls apoptosis after genotoxic stress by promoting PARP-1 cleavage. Mol Cell. 2022 02 17; 82(4):785-802.e10. View Abstract
30. Decidual NK cells kill Zika virus-infected trophoblasts. Proc Natl Acad Sci U S A. 2021 11 23; 118(47). View Abstract
31. Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study. PLoS One. 2021; 16(10):e0259061. View Abstract
32. NLRP3 inflammasome activation triggers gasdermin D-independent inflammation. Sci Immunol. 2021 Oct 22; 6(64):eabj3859. View Abstract
33. TRIM21 regulates pyroptotic cell death by promoting Gasdermin D oligomerization. Cell Death Differ. 2022 02; 29(2):439-450. View Abstract
34. SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. Res Sq. 2021 Aug 11. View Abstract
35. Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol. 2021 11; 21(11):694-703. View Abstract
36. The Lysosomal Rag-Ragulator Complex Licenses RIPK1 and Caspase-8-mediated Pyroptosis by Yersinia. Science. 2021 06 25; 372(6549). View Abstract
37. STING inhibitors target the cyclic dinucleotide binding pocket. Proc Natl Acad Sci U S A. 2021 06 15; 118(24). View Abstract
38. Gasdermin D pore structure reveals preferential release of mature interleukin-1. Nature. 2021 05; 593(7860):607-611. View Abstract
39. Channelling inflammation: gasdermins in physiology and disease. Nat Rev Drug Discov. 2021 05; 20(5):384-405. View Abstract
40. SARS-CoV-2 infects blood monocytes to activate NLRP3 and AIM2 inflammasomes, pyroptosis and cytokine release. medRxiv. 2021 Mar 08. View Abstract
41. Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown. Proc Natl Acad Sci U S A. 2021 03 02; 118(9). View Abstract
42. ?d T cells suppress Plasmodium falciparum blood-stage infection by direct killing and phagocytosis. Nat Immunol. 2021 03; 22(3):347-357. View Abstract
43. Lighting a Fire: Can We Harness Pyroptosis to Ignite Antitumor Immunity? Cancer Immunol Res. 2021 01; 9(1):2-7. View Abstract
44. Lighting a fire on the reef. Sci Immunol. 2020 12 04; 5(54). View Abstract
45. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 2020 11; 6(47). View Abstract
46. SARS-CoV-2 Nsp1 suppresses host but not viral translation through a bipartite mechanism. bioRxiv. 2020 Sep 18. View Abstract
47. Contributions of IFN-? and granulysin to the clearance of Plasmodium yoelii blood stage. PLoS Pathog. 2020 09; 16(9):e1008840. View Abstract
48. Decidual NK Cells Transfer Granulysin to Selectively Kill Bacteria in Trophoblasts. Cell. 2020 09 03; 182(5):1125-1139.e18. View Abstract
49. Tombusvirus p19 Captures RNase III-Cleaved Double-Stranded RNAs Formed by Overlapping Sense and Antisense Transcripts in Escherichia coli. mBio. 2020 06 09; 11(3). View Abstract
50. FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol. 2020 07; 21(7):736-745. View Abstract
51. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020 03; 579(7799):415-420. View Abstract
52. Knocking 'em Dead: Pore-Forming Proteins in Immune Defense. Annu Rev Immunol. 2020 04 26; 38:455-485. View Abstract
53. Correction: G3BP-Caprin1-USP10 complexes mediate stress granule condensation and associate with 40S subunits. J Cell Biol. 2020 Jan 06; 219(1). View Abstract
54. Gasdermin D activity in inflammation and host defense. Sci Immunol. 2019 09 06; 4(39). View Abstract
55. Granulysin: killer lymphocyte safeguard against microbes. Curr Opin Immunol. 2019 10; 60:19-29. View Abstract
56. Tumor-secreted extracellular vesicles promote the activation of cancer-associated fibroblasts via the transfer of microRNA-125b. J Extracell Vesicles. 2019; 8(1):1599680. View Abstract
57. Myeloid Cells in Intact Human Cervical Explants Capture HIV and Can Transmit It to CD4 T Cells. Front Immunol. 2018; 9:2719. View Abstract
58. Unveiling the RNA World. N Engl J Med. 2018 09 27; 379(13):1278-1280. View Abstract
59. Cytotoxic CD8+ T cells recognize and kill Plasmodium vivax-infected reticulocytes. Nat Med. 2018 09; 24(9):1330-1336. View Abstract
60. miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med. 2018 08 06; 215(8):2115-2136. View Abstract
61. PNPT1 Release from Mitochondria during Apoptosis Triggers Decay of Poly(A) RNAs. Cell. 2018 06 28; 174(1):187-201.e12. View Abstract
62. Cryo-EM structure of the gasdermin A3 membrane pore. Nature. 2018 05; 557(7703):62-67. View Abstract
63. Resistance of HIV-infected macrophages to CD8+ T lymphocyte-mediated killing drives activation of the immune system. Nat Immunol. 2018 05; 19(5):475-486. View Abstract
64. Tapping the RNA world for therapeutics. Nat Struct Mol Biol. 2018 05; 25(5):357-364. View Abstract
65. Diagnostic Potential of Imaging Flow Cytometry. Trends Biotechnol. 2018 07; 36(7):649-652. View Abstract
66. A modular platform for targeted RNAi therapeutics. Nat Nanotechnol. 2018 03; 13(3):214-219. View Abstract
67. Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. JCI Insight. 2017 11 02; 2(21). View Abstract
68. Granzyme B Disrupts Central Metabolism and Protein Synthesis in Bacteria to Promote an Immune Cell Death Program. Cell. 2017 Nov 16; 171(5):1125-1137.e11. View Abstract
69. Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. Mol Cancer Ther. 2017 Dec; 16(12):2849-2861. View Abstract
70. Chemoattractant-mediated leukocyte trafficking enables HIV dissemination from the genital mucosa. JCI Insight. 2017 04 06; 2(7):e88533. View Abstract
71. A Mechanistic Understanding of Pyroptosis: The Fiery Death Triggered by Invasive Infection. Adv Immunol. 2017; 135:81-117. View Abstract
72. Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer. Cell Res. 2017 Apr; 27(4):461-482. View Abstract
73. How ICE lights the pyroptosis fire. Cell Death Differ. 2017 02; 24(2):197-199. View Abstract
74. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016 07 07; 535(7610):153-8. View Abstract
75. TREX1 Knockdown Induces an Interferon Response to HIV that Delays Viral Infection in Humanized Mice. Cell Rep. 2016 05 24; 15(8):1715-27. View Abstract
76. An Epigenetic Clock Measures Accelerated Aging in Treated HIV Infection. Mol Cell. 2016 04 21; 62(2):153-155. View Abstract
77. G3BP-Caprin1-USP10 complexes mediate stress granule condensation and associate with 40S subunits. J Cell Biol. 2016 Mar 28; 212(7):845-60. View Abstract
78. Cytotoxic T Cells Use Mechanical Force to Potentiate Target Cell Killing. Cell. 2016 Mar 24; 165(1):100-110. View Abstract
79. Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites. Nat Med. 2016 Feb; 22(2):210-6. View Abstract
80. Capture and Identification of miRNA Targets by Biotin Pulldown and RNA-seq. Methods Mol Biol. 2016; 1358:211-28. View Abstract
81. Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci U S A. 2016 Jan 05; 113(1):E16-22. View Abstract
82. Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet. 2015 Sep; 16(9):543-52. View Abstract
83. Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells. Mol Cancer Ther. 2015 Oct; 14(10):2279-91. View Abstract
84. Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol. 2015 Aug; 33(8):870-6. View Abstract
85. miR-34 and p53: New Insights into a Complex Functional Relationship. PLoS One. 2015; 10(7):e0132767. View Abstract
86. Manipulating the in vivo immune response by targeted gene knockdown. Curr Opin Immunol. 2015 Aug; 35:63-72. View Abstract
87. A High Yield and Cost-efficient Expression System of Human Granzymes in Mammalian Cells. J Vis Exp. 2015 Jun 10; (100):e52911. View Abstract
88. An RNA-binding Protein, Lin28, Recognizes and Remodels G-quartets in the MicroRNAs (miRNAs) and mRNAs It Regulates. J Biol Chem. 2015 Jul 17; 290(29):17909-17922. View Abstract
89. Cytotoxic Cells Kill Intracellular Bacteria through Granulysin-Mediated Delivery of Granzymes. Cell. 2015 May 21; 161(5):1229. View Abstract
90. Apoptosis Triggers Specific, Rapid, and Global mRNA Decay with 3' Uridylated Intermediates Degraded by DIS3L2. Cell Rep. 2015 May 19; 11(7):1079-89. View Abstract
91. Ex vivo cytosolic delivery of functional macromolecules to immune cells. PLoS One. 2015; 10(4):e0118803. View Abstract
92. The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation. Cell Rep. 2015 Apr 07; 11(1):111-24. View Abstract
93. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 2015 Mar 17; 8(368):re3. View Abstract
94. Harnessing RNA interference for therapy: the silent treatment. JAMA. 2015 Mar 24-31; 313(12):1207-8. View Abstract
95. miR-200-containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest. 2014 Dec; 124(12):5109-28. View Abstract
96. G-quadruplex structures contribute to the neuroprotective effects of angiogenin-induced tRNA fragments. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18201-6. View Abstract
97. Developing an Effective Rectal Microbicide: Inhibiting HIV Transmission in Human Colorectal Tissue and Humanized Mice with CD4 Aptamer-siRNA Chimeras. AIDS Res Hum Retroviruses. 2014 Oct; 30 Suppl 1:A206. View Abstract
98. Inhibiting the Host Exonuclease TREX1 Induces a Localized and Protective Host Interferon Response against Acute HIV Infection In Vivo. AIDS Res Hum Retroviruses. 2014 Oct; 30 Suppl 1:A41. View Abstract
99. Sequencing of captive target transcripts identifies the network of regulated genes and functions of primate-specific miR-522. Cell Rep. 2014 Aug 21; 8(4):1225-39. View Abstract
100. Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus. Cell Rep. 2014 Aug 07; 8(3):714-22. View Abstract
101. Cytotoxic cells kill intracellular bacteria through granulysin-mediated delivery of granzymes. Cell. 2014 Jun 05; 157(6):1309-1323. View Abstract
102. Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer. Cancer Res. 2014 Jul 01; 74(13):3603-16. View Abstract
103. Leukocyte protease binding to nucleic acids promotes nuclear localization and cleavage of nucleic acid binding proteins. J Immunol. 2014 Jun 01; 192(11):5390-7. View Abstract
104. Distribution of immune cells in the human cervix and implications for HIV transmission. Am J Reprod Immunol. 2014 Mar; 71(3):252-64. View Abstract
105. Perforin: a key pore-forming protein for immune control of viruses and cancer. Subcell Biochem. 2014; 80:197-220. View Abstract
106. Production of highly potent recombinant siRNAs in Escherichia coli. Nat Protoc. 2013 Dec; 8(12):2325-36. View Abstract
107. Arf-like GTPase Arl8b regulates lytic granule polarization and natural killer cell-mediated cytotoxicity. Mol Biol Cell. 2013 Dec; 24(23):3721-35. View Abstract
108. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell. 2013 Aug 12; 24(2):182-96. View Abstract
109. Live or let die: posttranscriptional gene regulation in cell stress and cell death. Immunol Rev. 2013 May; 253(1):237-52. View Abstract
110. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther. 2013 Jul; 21(7):1378-89. View Abstract
111. Noncoding RNAs and cancer. Cell. 2013 Mar 28; 153(1):9-10. View Abstract
112. Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol. 2013 Apr; 31(4):350-6. View Abstract
113. Identification of regulators of the innate immune response to cytosolic DNA and retroviral infection by an integrative approach. Nat Immunol. 2013 Feb; 14(2):179-85. View Abstract
114. SAMHD1 does it again, now in resting T cells. Nat Med. 2012 Nov; 18(11):1611-2. View Abstract
115. Alterations in RNA processing during immune-mediated programmed cell death. Proc Natl Acad Sci U S A. 2012 May 29; 109(22):8688-93. View Abstract
116. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med. 2012 Apr 18; 4(130):130ra48. View Abstract
117. Bone morphogenetic protein 4 promotes vascular smooth muscle contractility by activating microRNA-21 (miR-21), which down-regulates expression of family of dedicator of cytokinesis (DOCK) proteins. J Biol Chem. 2012 Feb 03; 287(6):3976-86. View Abstract
118. Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling. PLoS Genet. 2011 Nov; 7(11):e1002363. View Abstract
119. Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell. 2011 Oct 14; 147(2):344-57. View Abstract
120. Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet. 2011 Sep; 7(9):e1002242. View Abstract
121. Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine. 2011 Aug 05; 29(34):5611-22. View Abstract
122. Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. Nat Immunol. 2011 Jun 19; 12(8):770-7. View Abstract
123. HIV DNA is heavily uracilated, which protects it from autointegration. Proc Natl Acad Sci U S A. 2011 May 31; 108(22):9244-9. View Abstract
124. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest. 2011 Jun; 121(6):2401-12. View Abstract
125. Prior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV. J Immune Based Ther Vaccines. 2011 Jan 18; 9:2. View Abstract
126. Gaining a foothold: how HIV avoids innate immune recognition. Curr Opin Immunol. 2011 Feb; 23(1):21-8. View Abstract
127. Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol. 2011 Feb 20; 29(6):747-54. View Abstract
128. Desperately seeking microRNA targets. Nat Struct Mol Biol. 2010 Oct; 17(10):1169-74. View Abstract
129. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol. 2010 Nov; 11(11):1005-13. View Abstract
130. Small RNAs guide hematopoietic cell differentiation and function. J Immunol. 2010 Jun 01; 184(11):5939-47. View Abstract
131. Isolation of cytotoxic T cell and NK granules and purification of their effector proteins. Curr Protoc Cell Biol. 2010 Jun; Chapter 3:Unit3.37. View Abstract
132. Anatomy of a murder: how cytotoxic T cells and NK cells are activated, develop, and eliminate their targets. Immunol Rev. 2010 May; 235(1):5-9. View Abstract
133. Granzyme A activates another way to die. Immunol Rev. 2010 May; 235(1):93-104. View Abstract
134. Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients. J Immunol. 2010 Apr 01; 184(7):4025-32. View Abstract
135. Perforin activates clathrin- and dynamin-dependent endocytosis, which is required for plasma membrane repair and delivery of granzyme B for granzyme-mediated apoptosis. Blood. 2010 Feb 25; 115(8):1582-93. View Abstract
136. Molecular basis for antagonism between PDGF and the TGFbeta family of signalling pathways by control of miR-24 expression. EMBO J. 2010 Feb 03; 29(3):559-73. View Abstract
137. Micromanaging cancer. N Engl J Med. 2009 Oct 08; 361(15):1500-1. View Abstract
138. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One. 2009 Sep 29; 4(9):e7181. View Abstract
139. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell. 2009 Sep 11; 35(5):610-25. View Abstract
140. Micromanipulating cancer: microRNA-based therapeutics? RNA Biol. 2009 Jul-Aug; 6(3):335-40. View Abstract
141. miR-34a contributes to megakaryocytic differentiation of K562 cells independently of p53. Blood. 2009 Sep 03; 114(10):2181-92. View Abstract
142. Numbers matter: quantitative and dynamic analysis of the formation of an immunological synapse using imaging flow cytometry. J Immunol Methods. 2009 Aug 15; 347(1-2):79-86. View Abstract
143. The cytotoxic T lymphocyte protease granzyme A cleaves and inactivates poly(adenosine 5'-diphosphate-ribose) polymerase-1. Blood. 2009 Aug 06; 114(6):1205-16. View Abstract
144. Harvard's women four years later. Nat Immunol. 2009 Jun; 10(6):559-61. View Abstract
145. miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol. 2009 May; 16(5):492-8. View Abstract
146. The SET complex acts as a barrier to autointegration of HIV-1. PLoS Pathog. 2009 Mar; 5(3):e1000327. View Abstract
147. Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe. 2009 Jan 22; 5(1):84-94. View Abstract
148. Micromanagers of immune cell fate and function. Adv Immunol. 2009; 102:227-44. View Abstract
149. RIG-ing an antitumor response. Nat Med. 2008 Nov; 14(11):1152-3. View Abstract
150. Identification and characterization of PWWP domain residues critical for LEDGF/p75 chromatin binding and human immunodeficiency virus type 1 infectivity. J Virol. 2008 Dec; 82(23):11555-67. View Abstract
151. Whither or wither microbicides? Science. 2008 Jul 25; 321(5888):532-4. View Abstract
152. A PP4-phosphatase complex dephosphorylates gamma-H2AX generated during DNA replication. Mol Cell. 2008 Jul 11; 31(1):33-46. View Abstract
153. Granzyme A cleaves a mitochondrial complex I protein to initiate caspase-independent cell death. Cell. 2008 May 16; 133(4):681-92. View Abstract
154. p16(INK4a) translation suppressed by miR-24. PLoS One. 2008 Mar 26; 3(3):e1864. View Abstract
155. Identification of host proteins required for HIV infection through a functional genomic screen. Science. 2008 Feb 15; 319(5865):921-6. View Abstract
156. Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol. 2008; 26:389-420. View Abstract
157. RNA interference and cancer: endogenous pathways and therapeutic approaches. Adv Exp Med Biol. 2008; 615:299-329. View Abstract
158. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007 Dec 14; 131(6):1109-23. View Abstract
159. Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys. Vaccine. 2007 Oct 16; 25(42):7470-9. View Abstract
160. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007 Sep; 39(9):1065-7. View Abstract
161. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007 Jun; 6(6):443-53. View Abstract
162. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med (Berl). 2007 May; 85(5):531-7. View Abstract
163. Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol. 2007 Jun; 19(3):301-8. View Abstract
164. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci U S A. 2007 Mar 06; 104(10):4095-100. View Abstract
165. NFAT5 regulates HIV-1 in primary monocytes via a highly conserved long terminal repeat site. PLoS Pathog. 2006 Dec; 2(12):e130. View Abstract
166. Knocking down disease with siRNAs. Cell. 2006 Jul 28; 126(2):231-5. View Abstract
167. Silencing viral infection. PLoS Med. 2006 Jul; 3(7):e242. View Abstract
168. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell. 2006 Jul 07; 23(1):133-42. View Abstract
169. Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism. Proc Natl Acad Sci U S A. 2006 Apr 11; 103(15):5953-8. View Abstract
170. The silent treatment: siRNAs as small molecule drugs. Gene Ther. 2006 Mar; 13(6):541-52. View Abstract
171. Granzyme A, which causes single-stranded DNA damage, targets the double-strand break repair protein Ku70. EMBO Rep. 2006 Apr; 7(4):431-7. View Abstract
172. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu Rev Biomed Eng. 2006; 8:377-402. View Abstract
173. gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell. 2005 Dec 09; 20(5):801-9. View Abstract
174. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature. 2006 Jan 05; 439(7072):89-94. View Abstract
175. A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery. Nature. 2006 Jan 26; 439(7075):497-501. View Abstract
176. Perforin triggers a plasma membrane-repair response that facilitates CTL induction of apoptosis. Immunity. 2005 Sep; 23(3):249-62. View Abstract
177. Listeria-infected myeloid dendritic cells produce IFN-beta, priming T cell activation. J Immunol. 2005 Jul 01; 175(1):421-32. View Abstract
178. Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epidermal keratinocytes: a novel strategy for immune evasion. J Virol. 2005 Jun; 79(12):7363-70. View Abstract
179. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 2005 Jun; 23(6):709-17. View Abstract
180. Granzyme B binds to target cells mostly by charge and must be added at the same time as perforin to trigger apoptosis. J Immunol. 2005 May 01; 174(9):5456-61. View Abstract
181. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. Blood. 2005 Aug 01; 106(3):818-26. View Abstract
182. The prospect of silencing disease using RNA interference. JAMA. 2005 Mar 16; 293(11):1367-73. View Abstract
183. Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis. Immunity. 2005 Mar; 22(3):355-70. View Abstract
184. Adenovirus protein VII functions throughout early phase and interacts with cellular proteins SET and pp32. J Virol. 2005 Feb; 79(4):2474-83. View Abstract
185. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med. 2005; 56:401-23. View Abstract
186. Cross-clade CD8 T-cell responses to HIV(IIIB) and Chinese B' and C/B' viruses in North American and Chinese HIV-seropositive donors. J Acquir Immune Defic Syndr. 2004 Dec 01; 37(4):1435-44. View Abstract
187. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2004 Oct 12; 101(41):14883-8. View Abstract
188. Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function. Immunology. 2004 Aug; 112(4):531-42. View Abstract
189. Tracking the killers: how should we measure CD8 T cells in HIV infection? AIDS. 2004 Jul 23; 18(11):1489-93. View Abstract
190. Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS. 2004 Mar 05; 18(4):605-13. View Abstract
191. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science. 2004 Jan 16; 303(5656):316. View Abstract
192. Nuclear war: the granzyme A-bomb. Curr Opin Immunol. 2003 Oct; 15(5):553-9. View Abstract
193. Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine. 2003 Oct 01; 21(27-30):4486-504. View Abstract
194. The Bcl-2 family pro-apoptotic molecule, BNIP3 regulates activation-induced cell death of effector cytotoxic T lymphocytes. Immunology. 2003 Sep; 110(1):10-7. View Abstract
195. Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med. 2003 Sep; 9(9):397-403. View Abstract
196. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol. 2003 Jul; 77(13):7174-81. View Abstract
197. A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen. Proc Natl Acad Sci U S A. 2003 May 27; 100(11):6652-7. View Abstract
198. The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol. 2003 May; 3(5):361-70. View Abstract
199. The gp49B1 inhibitory receptor regulates the IFN-gamma responses of T cells and NK cells. J Immunol. 2003 Apr 15; 170(8):4095-101. View Abstract
200. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003 Mar 07; 112(5):659-72. View Abstract
201. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003 Mar; 9(3):347-51. View Abstract
202. Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol. 2003 Feb; 4(2):145-53. View Abstract
203. HIV-1 antiviral activity of recombinant natural killer cell enhancing factors, NKEF-A and NKEF-B, members of the peroxiredoxin family. J Biol Chem. 2003 Jan 17; 278(3):1569-74. View Abstract
204. The functional CD8 T cell response to HIV becomes type-specific in progressive disease. J Clin Invest. 2002 Nov; 110(9):1339-47. View Abstract
205. Defying death--HIV mutation to evade cytotoxic T lymphocytes. N Engl J Med. 2002 Oct 10; 347(15):1203-4. View Abstract
206. Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood. 2003 Jan 01; 101(1):226-35. View Abstract
207. Avoiding the kiss of death: how HIV and other chronic viruses survive. Curr Opin Immunol. 2002 Aug; 14(4):478-86. View Abstract
208. siRNA-directed inhibition of HIV-1 infection. Nat Med. 2002 Jul; 8(7):681-6. View Abstract
209. Engineered Listeria monocytogenes as an AIDS vaccine. Vaccine. 2002 May 06; 20(15):2007-10. View Abstract
210. HMG2 interacts with the nucleosome assembly protein SET and is a target of the cytotoxic T-lymphocyte protease granzyme A. Mol Cell Biol. 2002 Apr; 22(8):2810-20. View Abstract
211. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood. 2001 Sep 15; 98(6):1667-77. View Abstract
212. Granzyme A activates an endoplasmic reticulum-associated caspase-independent nuclease to induce single-stranded DNA nicks. J Biol Chem. 2001 Nov 16; 276(46):43285-93. View Abstract
213. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest. 2001 Sep; 108(6):871-8. View Abstract
214. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. Blood. 2001 Jul 01; 98(1):156-64. View Abstract
215. Direct cleavage of the human DNA fragmentation factor-45 by granzyme B induces caspase-activated DNase release and DNA fragmentation. EMBO J. 2001 Jun 15; 20(12):3101-13. View Abstract
216. Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis. Proc Natl Acad Sci U S A. 2001 May 08; 98(10):5746-51. View Abstract
217. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J Virol. 2000 Nov; 74(21):9987-93. View Abstract
218. Impaired function of circulating HIV-specific CD8(+) T cells in chronic human immunodeficiency virus infection. Blood. 2000 Nov 01; 96(9):3094-101. View Abstract
219. Induction of rapid histone degradation by the cytotoxic T lymphocyte protease Granzyme A. J Biol Chem. 2001 Feb 02; 276(5):3683-90. View Abstract
220. Impact of intestinal ischemia-reperfusion on cytokine profile and enterocyte viability in human syngeneic intestinal transplantation. Transplant Proc. 2000 Sep; 32(6):1292-3. View Abstract
221. Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol. 2000 Aug; 74(16):7320-30. View Abstract
222. CD3zeta and CD28 down-modulation on CD8 T cells during viral infection. Blood. 2000 Aug 01; 96(3):1021-9. View Abstract
223. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity. Proc Natl Acad Sci U S A. 2000 Jul 05; 97(14):8027-32. View Abstract
224. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis. 1999 Dec; 180(6):1827-32. View Abstract
225. A transgenic mouse model to analyze CD8(+) effector T cell differentiation in vivo. Proc Natl Acad Sci U S A. 1999 Nov 23; 96(24):13932-7. View Abstract
226. Viral-specific cytotoxic T lymphocytes lyse human immunodeficiency virus-infected primary T lymphocytes by the granule exocytosis pathway. Blood. 1999 Nov 01; 94(9):3084-93. View Abstract
227. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters. AIDS Res Hum Retroviruses. 1999 Oct 10; 15(15):1333-8. View Abstract
228. Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. AIDS. 1999 Jul 30; 13(11):1295-303. View Abstract
229. Expansion of CD57 and CD62L-CD45RA+ CD8 T lymphocytes correlates with reduced viral plasma RNA after primary HIV infection. AIDS. 1999 May 28; 13(8):891-9. View Abstract
230. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999 May 27; 340(21):1683-4. View Abstract
231. Clonal expansion of antigen-specific CD8+ cytotoxic T lymphocytes is regulated by late exposure to serum to prevent apoptosis. J Immunol Methods. 1999 May 27; 225(1-2):39-52. View Abstract
232. Granzyme A loading induces rapid cytolysis and a novel form of DNA damage independently of caspase activation. Immunity. 1999 May; 10(5):585-94. View Abstract
233. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res Hum Retroviruses. 1999 May 01; 15(7):619-24. View Abstract
234. Mitochondria-dependent and -independent regulation of Granzyme B-induced apoptosis. J Exp Med. 1999 Jan 04; 189(1):131-44. View Abstract
235. Effective lysis of HIV-1-infected primary CD4+ T cells by a cytotoxic T-lymphocyte clone directed against a novel A2-restricted reverse-transcriptase epitope. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 01; 19(2):111-20. View Abstract
236. A role for heat shock protein 27 in CTL-mediated cell death. J Immunol. 1998 Jul 01; 161(1):161-7. View Abstract
237. Expression and purification of enzymatically active recombinant granzyme B in a baculovirus system. Biochem Biophys Res Commun. 1998 Feb 13; 243(2):384-9. View Abstract
238. Circulating CD8 T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 zeta, the signaling chain of the T-cell receptor complex. Blood. 1998 Jan 15; 91(2):585-94. View Abstract
239. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood. 1997 Sep 15; 90(6):2196-206. View Abstract
240. Recombinant human granzyme A binds to two putative HLA-associated proteins and cleaves one of them. Proc Natl Acad Sci U S A. 1997 Aug 19; 94(17):9285-90. View Abstract
241. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood. 1997 Jun 01; 89(11):4167-74. View Abstract
242. Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocytes response to HIV type 1 in an infected individual. AIDS Res Hum Retroviruses. 1997 Mar 20; 13(5):383-92. View Abstract
243. EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice. Immunol Lett. 1996 Sep; 52(2-3):145-52. View Abstract
244. Three regions of HIV-1 gp160 contain clusters of immunodominant CTL epitopes. Immunol Lett. 1996 Aug; 52(1):23-30. View Abstract
245. The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients. J Exp Med. 1996 Jul 01; 184(1):283-8. View Abstract
246. Effect of interleukin 12 on in vitro HIV type 1 replication depends on clinical stage. AIDS Res Hum Retroviruses. 1996 May 20; 12(8):659-68. View Abstract
247. Prediction of HIV peptide epitopes by a novel algorithm. AIDS Res Hum Retroviruses. 1996 May 01; 12(7):593-610. View Abstract
248. Induction of cell-mediated immune responses to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. J Immunol. 1995 Nov 15; 155(10):4775-82. View Abstract
249. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Sep 01; 10(1):27-35. View Abstract
250. Enhanced susceptibility to human immunodeficiency virus infection in CD4+ T lymphocytes genetically deficient in CD43. AIDS Res Hum Retroviruses. 1995 Sep; 11(9):1015-21. View Abstract
251. A simple method to selectively expand HIV-1 specific cytotoxic T lymphocytes in vitro. Immunol Invest. 1995 Mar; 24(3):489-97. View Abstract
252. CD43 diminishes susceptibility to T lymphocyte-mediated cytolysis. J Immunol. 1995 Feb 01; 154(3):1097-104. View Abstract
253. Ex vivo expansion of HIV type 1-specific cytolytic T cells from HIV type 1-seropositive subjects. AIDS Res Hum Retroviruses. 1995 Feb; 11(2):257-71. View Abstract
254. Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retroviruses. 1994 Dec; 10(12):1703-11. View Abstract
255. Using T cells to treat B-cell cancers. N Engl J Med. 1994 Apr 28; 330(17):1231-3. View Abstract
Show All Publications Show Fewer Publications